Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia

In chronic myelogenous leukemia (CML), treatment-free remission (TFR) is defined as maintaining a major molecular response (MMR) without a tyrosine kinase inhibitor (TKI), such as imatinib (IM). Several studies have investigated the safety of the first TFR (TFR(1)) attempt and suggested recommendati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eunjung, Hwang, Eo-Jin, Lee, Junghye, Kim, Dae-Young, Kim, Jae-Young, Kim, Dong-Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309666/
https://www.ncbi.nlm.nih.gov/pubmed/35878453
http://dx.doi.org/10.1016/j.neo.2022.100817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309666/
https://www.ncbi.nlm.nih.gov/pubmed/35878453
http://dx.doi.org/10.1016/j.neo.2022.100817

Ejemplares similares